TB-500

Molecular Profile

Type

Synthetic peptide (Thymosin Beta-4 related)

Molecular formula

C212H350N56O78S

Molecular weight

~4,963 g/mol

CAS number

77591-33-4

Amino acids

43

Sequence

Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES

Modification

N-terminal acetylation. Two distinct molecules are marketed under this name: full-length Thymosin Beta-4 (Tβ4; 43 residues; CAS 77591-33-4) and the actin-binding fragment Ac-LKKTETQ (residues 17-23; CAS 885340-08-9). Most published in vivo and clinical research has examined the full-length peptide, not the short fragment; the two are studied as separate molecules.

Mechanism & Target Class

Thymosin Beta-4 is the principal intracellular G-actin-sequestering peptide; the LKKTETQ motif is its actin-binding domain. It binds monomeric actin and modulates actin polymerization rather than acting through a cell-surface receptor.

Storage & Handling

Lyophilized

-20°C; ~24 months desiccated and protected from light.

Handling

Highly water-soluble; protect from light; aliquot; salt form affects exact mass.

Primary Database

PubChem CID 45382195 ↗

References (55)

1. Reviews

   1

   Kleinman HK, et al. (2023). Int Immunopharmacology

   DOI: 10.1016/j.intimp.2022.109628PubMed 36580759

2. 2

   Sosne G, Berger EA. (2023). Int Immunopharmacol

   PubMed 37018981

3. 3

   Sosne G. (2018). Expert Opin Biol Ther

   PubMed 30063853

4. 4

   Dubé KN, Smart N. (2018). Expert Opin Biol Ther

   DOI: 10.1080/14712598.2018.1459558PubMed 30063849

5. 5

   Kleinman HK, Sosne G. (2016). Vitam Horm

   PubMed 27450738

6. 6

   Sosne G, Kleinman HK. (2015). Invest Ophthalmol Vis Sci

   DOI: 10.1167/iovs.15-16890PubMed 26241398

7. 7

   Morris DC, et al. (2012). Ann NY Acad Sci

   DOI: 10.1111/j.1749-6632.2012.06651.xPubMed 23045978

8. 8

   Goldstein AL, et al. (2012). Expert Opin Biol Ther

   DOI: 10.1517/14712598.2012.634793PubMed 22074294

9. 9

   Crockford D, et al. (2010). Ann NY Acad Sci

   DOI: 10.1111/j.1749-6632.2010.05492.x

10. 10

    Hannappel E. (2007). Ann NY Acad Sci

    PubMed 17947587

11. 11

    Goldstein AL, et al. (2005). Trends Mol Med

    DOI: 10.1016/j.molmed.2005.07.004PubMed 16099219

12. Clinical

    12

    Sosne G, et al. (2022). Int J Mol Sci

    DOI: 10.3390/ijms24010554PubMed 36613994

13. 13

    Sosne G, Ousler GW. (2015). Clin Ophthalmol

    DOI: 10.2147/OPTH.S80954PubMed 26056426

14. 14

    Sosne G, et al. (2015). Cornea

    PubMed 25826322

15. 15

    Ruff D, et al. (2010). Ann NY Acad Sci

    DOI: 10.1111/j.1749-6632.2010.05474.xPubMed 20536472

16. 16

    ClinicalTrials.gov. ClinicalTrials.gov

    NCT05984134

17. 17

    ClinicalTrials.gov. ClinicalTrials.gov

    NCT05555589

18. 18

    ClinicalTrials.gov. ClinicalTrials.gov

    NCT05485818

19. 19

    ClinicalTrials.gov. ClinicalTrials.gov

    NCT02974907

20. 20

    ClinicalTrials.gov. ClinicalTrials.gov

    NCT02597803

21. 21

    ClinicalTrials.gov. ClinicalTrials.gov

    NCT01311518

22. 22

    ClinicalTrials.gov. ClinicalTrials.gov

    NCT00832091

23. 23

    ClinicalTrials.gov. ClinicalTrials.gov

    NCT00382174

24. 24

    ClinicalTrials.gov. ClinicalTrials.gov

    NCT00311766

25. 25

    ClinicalTrials.gov. ClinicalTrials.gov

    NCT03578029

26. Primary research

    26

    Kim S, Choi J, Kwon J. (2023). Molecules

    DOI: 10.3390/molecules28093920

27. 27

    Tan SH, et al. (2021). Theranostics

    DOI: 10.7150/thno.56757

28. 28

    Kim S, Kwon J. (2018). Sci Rep

    DOI: 10.1038/s41598-018-28861-5

29. 29

    Li H, et al. (2018). J Gene Med

    DOI: 10.1002/jgm.3043PubMed 29972714

30. 30

    Kim J, Jung Y. (2017). Sci Rep

    DOI: 10.1038/s41598-017-06318-5

31. 31

    Hong Y, et al. (2017). Biochem Biophys Res Commun

    DOI: 10.1016/j.bbrc.2017.09.156PubMed 28965947

32. 32

    Zhang J, et al. (2016). Neurobiol Dis

    PubMed 26805386

33. 33

    Cheng P, et al. (2014). Neuropharmacology

    DOI: 10.1016/j.neuropharm.2014.06.004PubMed 24937047

34. 34

    Conte E, et al. (2013). Eur J Clin Invest

    DOI: 10.1111/eci.12048PubMed 23320620

35. 35

    Wang L, et al. (2012). Neurobiol Dis

    DOI: 10.1016/j.nbd.2012.08.002PubMed 22922221

36. 36

    Xiong Y, et al. (2012). J Neurosurg

    DOI: 10.3171/2012.1.JNS111729PubMed 22324420

37. 37

    Didry D, et al. (2012). EMBO J

    DOI: 10.1038/emboj.2011.461PubMed 22193718

38. 38

    Esposito S, et al. (2012). Drug Test Anal

    DOI: 10.1002/dta.1402

39. 39

    Ho ENM, et al. (2012). J Chromatogr A

    DOI: 10.1016/j.chroma.2012.09.043

40. 40

    Smart N, et al. (2011). Nature

    DOI: 10.1038/nature10188

41. 41

    Morris DC, et al. (2010). Neuroscience

    DOI: 10.1016/j.neuroscience.2010.05.017PubMed 20627173

42. 42

    Zhang J, et al. (2009). Neuroscience

    DOI: 10.1016/j.neuroscience.2009.09.054PubMed 19782721

43. 43

    Smart N, et al. (2007). Nature

    DOI: 10.1038/nature05383PubMed 17108969

44. 44

    Philp D, et al. (2007). Ann NY Acad Sci

    DOI: 10.1196/annals.1415.009PubMed 17947589

45. 45

    Philp D, et al. (2006). J Cell Physiol

    DOI: 10.1002/jcp.20650

46. 46

    Bock-Marquette I, et al. (2004). Nature

    DOI: 10.1038/nature03000PubMed 15565145

47. 47

    Philp D, et al. (2004). FASEB J

    DOI: 10.1096/fj.03-0244fjePubMed 14657002

48. 48

    Irobi E, et al. (2004). EMBO J

    DOI: 10.1038/sj.emboj.7600372PubMed 15329672

49. 49

    Hertzog M, et al. (2004). Cell

    PubMed 15163409

50. 50

    Philp D, et al. (2003). FASEB J

    DOI: 10.1096/fj.03-0121fjePubMed 14500546

51. 51

    Sosne G, et al. (2002). Exp Eye Res

    DOI: 10.1006/exer.2001.1125PubMed 11950239

52. 52

    Grant DS, et al. (1999). Angiogenesis

    DOI: 10.1023/A:1009041911493PubMed 14517430

53. 53

    Malinda KM, et al. (1999). J Invest Dermatol

    DOI: 10.1046/j.1523-1747.1999.00708.x

54. 54

    Malinda KM, et al. (1997). FASEB J

    DOI: 10.1096/fasebj.11.6.9194528

55. 55

    Weber A, et al. (1992). Biochemistry

    DOI: 10.1021/bi00142a002PubMed 1627561